NeurologyPending review

Migraine

A primary headache disorder driven by transient neuronal and vascular dysfunction (cortical spreading depression generates the aura, trigeminovascular activation generates the pain), producing a stereotyped, self-limiting attack rather than a structural lesion.

In a nutshell

Migraine begins with a slow wave of cortical depolarisation, spreading depression, producing a gradually evolving aura, and activates trigeminal afferents around meningeal vessels to cause unilateral, throbbing pain with nausea and photophobia.

Classic presentation

A young adult with recurrent unilateral, throbbing headache lasting hours, accompanied by nausea, photophobia and phonophobia, occasionally preceded by an expanding visual aura.

Key points

  • Aura evolves gradually over minutes because cortical spreading depression is a slow wave: this distinguishes it from the abrupt onset of TIA or stroke.
  • Pain arises from trigeminovascular activation and neurogenic inflammation of meningeal vessels, explaining the throbbing quality and worsening with activity.
  • Triptans abort an attack by acting on the trigeminovascular pathway and must be taken early; preventive drugs raise the attack threshold instead.
  • Migraine is a clinical diagnosis; imaging is reserved for atypical features or red flags, not for typical presentations.
  • Frequent use of acute medication can itself cause medication overuse headache, perpetuating the cycle.

First-line investigation

None routinely: diagnosis is clinical, based on the stereotyped attack pattern; imaging is reserved for red flags or atypical features.

First-line management

Early acute treatment with an NSAID or triptan plus antiemetic, and preventive therapy if attacks are frequent or disabling.

Exam traps

  • Thunderclap headache maximal at onset is not migraine: it must trigger a subarachnoid haemorrhage work-up.
  • Aura lasting more than an hour with abrupt, not gradual, onset should raise concern for stroke or TIA, not be assumed to be migrainous.
  • Triptans are contraindicated in patients with cardiovascular or cerebrovascular disease because of their vasoconstrictive action, a common prescribing trap.

Educational content pending clinical review. Not medical advice.